By E. Janene Geiss
Philadelphia, Oct. 12 - Aerie Pharmaceuticals, Inc. said it raised $21 million in series A financing.
The lead investors were Alta Partners and Texas Pacific Group Ventures.
Geoff Duyk, a managing director at Texas Pacific Group Ventures, and David Mack, Ph.D., a director at Alta Partners, will join Aerie's board of directors, company officials said in an Oct. 12 press release.
Aerie said the financing will be used to fund phase I and phase II clinical studies of AR-101, a second generation of prostaglandin analogs with the potential to provide superior efficacy and an improved safety profile in glaucoma patients, officials said.
"This funding will accelerate our efforts to bring these innovative products to market," Tom van Haarlem, M.D., Aerie president and chief executive officer, said in the release.
Aerie Pharmaceuticals is located in Research Triangle Park, N.C., and focused on discovery and development of medical innovations in ophthalmology.
| Issuer: | Aerie Pharmaceuticals, Inc.
|
| Issue: | Series A financing
|
| Amount: | $21 million
|
| Investors: | Alta Partners, Texas Pacific Group Ventures
|
| Announcement date: | Oct. 12
|
|
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
